Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.

[1]  Florian Kronenberg,et al.  Development and validation of a predictive mortality risk score from a European hemodialysis cohort , 2015, Kidney international.

[2]  M. Burnier,et al.  Drug adherence in chronic kidney diseases and dialysis. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  C. Ghossein,et al.  A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[4]  A. Rastogi,et al.  Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence , 2013, BMC Nephrology.

[5]  K. Mahaffey,et al.  Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. , 2012, The New England journal of medicine.

[6]  D. Cukor,et al.  Depression and nonadherence predict mortality in hemodialysis treated end‐stage renal disease patients , 2012, Hemodialysis international. International Symposium on Home Hemodialysis.

[7]  M. Wolf,et al.  Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  H. Hemingway,et al.  Current prescribing of statins and persistence to statins following ACS in the UK: a MINAP/GPRD study , 2012 .

[9]  Florian Kronenberg,et al.  An Epidemiological Study of Hemodialysis Patients Based on the European Fresenius Medical Care Hemodialysis Network: Results of the ARO Study , 2010, Nephron Clinical Practice.

[10]  T. Browne,et al.  Barriers to adult hemodialysis patients' self-management of oral medications. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  A. Macleod,et al.  Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD) , 2009 .

[12]  B. Hartmann,et al.  Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: A critical review of the literature , 2009, European journal of medical research.

[13]  D. Goldsmith,et al.  Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  Supplemental Tables,et al.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). , 2009, Kidney international. Supplement.

[15]  P. Kerr,et al.  Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  K. Rothman,et al.  Consistent control of mineral and bone disorder in incident hemodialysis patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[17]  E. Bedrick,et al.  Mortality risk among hemodialysis patients receiving different vitamin D analogs. , 2006, Kidney international.

[18]  G. Eknoyan,et al.  Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.

[19]  R. Foley,et al.  Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. , 2005, Journal of the American Society of Nephrology : JASN.

[20]  B. Culleton,et al.  Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. , 2005, Journal of the American Society of Nephrology : JASN.

[21]  F. Locatelli,et al.  Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. , 2004, The New England journal of medicine.

[22]  H Steil,et al.  EuCliD® – A Medical Registry , 2004, Methods of Information in Medicine.

[23]  S. Rosansky,et al.  The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. , 2003, Journal of the American Society of Nephrology : JASN.

[24]  S. Moe,et al.  The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. , 2003, Kidney international.

[25]  S. Ganesh,et al.  Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. , 2001, Journal of the American Society of Nephrology : JASN.

[26]  F. Port,et al.  Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.